Addison Advisors’s Humacyte HUMA Stock Holding History

Addison Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-800	Closed	-$486	–	840
2026 Q1	$486	Hold	800	–	–	﹤0.01%	934
2025 Q4	$769	Hold	800	–	–	﹤0.01%	849
2025 Q3	$1.39K	Hold	800	–	–	﹤0.01%	799
2025 Q2	$1.67K	Hold	800	–	–	﹤0.01%	786
2025 Q1	$1.36K	Hold	800	–	–	﹤0.01%	767
2024 Q4	$4.04K	Hold	800	–	–	﹤0.01%	693
2024 Q3	$4.35K	Sell	800 -200	-20%	-$1.32K	﹤0.01%	680
2024 Q2	$4.8K	Hold	1,000	–	–	﹤0.01%	641
2024 Q1	$3.11K	Hold	1,000	–	–	﹤0.01%	606
2023 Q4	$2.84K	Hold	1,000	–	–	﹤0.01%	605
2023 Q3	$2.93K	Hold	1,000	–	–	﹤0.01%	571
2023 Q2	$2.86K	Hold	1,000	–	–	﹤0.01%	557
2023 Q1	$3.09K	Hold	1,000	–	–	﹤0.01%	536
2022 Q4	$2.11K	Hold	1,000	–	–	﹤0.01%	555
2022 Q3	$3K	Hold	1,000	–	–	﹤0.01%	536
2022 Q2	$3K	Buy	+1,000	New	+$5.56K	﹤0.01%	526

Other funds holding HUMA

Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Addison Advisors's HUMA Position: Q2 2026 in Review

Addison Advisors sold out of Humacyte (HUMA) in Q2 2026, closing a stake of 800 shares — an estimated $486 sold.

Addison Advisors first reported a position in HUMA in Q2 2022 and held it in 16 quarters. The position peaked at $4.8K in Q2 2024. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

Addison Advisors reported no remaining Humacyte position as of Q2 2026 after selling out during the quarter.
Addison Advisors sold 800 Humacyte shares in Q2 2026, an estimated $486.
Addison Advisors first reported a position in Humacyte in Q2 2022 and held it in 16 quarters.
Addison Advisors's Humacyte position peaked at $4.8K in Q2 2024.
161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Addison Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.